ArticleRespiratory research2026
Nerandomilast attenuates Pantoea agglomerans-induced hypersensitivity pneumonitis by regulating M1 macrophage polarization and fibroblast activation.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Formononetin ameliorates bleomycin-induced pulmonary fibrosis in mice via targeting USP5.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHypersensitivity pneumonitis (HP) is characterized by bronchiolocentric inflammation and fibrosis. The characteristic pathological features include bronchiolocentric inflammation, peribronchiolar fibrosis, and the presence of poorly formed granulomas. Nerandomilast is a novel oral phosphodiesterase 4 (PDE4) inhibitor with good selectivity for PDE4B. PDE4 inhibitors (PDE4i) exhibit anti-inflammatory/antifibrotic properties, the efficacy of nerandomilast remains unexplored in HP.
methodsWe selected macrophages and fibroblasts as effector cells for the inflammatory and fibrotic phases of HP in vitro. And we established in vivo HP models induced by saline extract of the cells of P. agglomerans (SE-PA).
resultsThe results of the in vitro studies revealed that nerandomilast inhibited the expression of proinflammatory markers (i.e., CD86, iNOS, and IL-1β) of M1 macrophages by increasing CREB phosphorylation and inhibiting the NF-κB signaling pathway. Furthermore, nerandomilast reduced TGFβ1-induced fibroblast activation by inhibiting Smad and non-Smad signaling pathways. In vivo studies confirmed that nerandomilast could reduce the number of inflammatory cells in bronchoalveolar lavage fluid and the secretion of proinflammatory cytokines (such as IL-1β, IL-6, and TNF-α), lower the serum levels of the oxidative stress markers MPO and MDA, and inhibit the transcription of proinflammatory cytokines in lung tissue. Moreover, nerandomilast alleviated pulmonary fibrosis and pulmonary dysfunction in mice with HP induced by SE-PA.
conclusionOur findings indicated that nerandomilast might attenuate inflammation and fibrosis in SE-PA-induced HP mice by regulating macrophage polarization and inhibiting fibroblast activation, which provides new insights for the clinical treatment of HP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.